Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections
Shakti Singh, Eman G. Youssef, Ashley Barbarino, Haley Hautau, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Gary Ostroff, Dennis Christensen, Terrence Cochrane, Ashraf S. Ibrahim · 2025
Read Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections by Shakti Singh, Eman G. Youssef, Ashley Barbarino, Haley Hautau, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Gary Ostroff, Dennis Christensen, Terrence Cochrane, Ashraf S. Ibrahim (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12819413.txt.
Description
Shakti Singh and colleagues tested a next-generation vaccine against Candida fungi in 2025. Candida species cause surface and deep invasive infections, and drug resistance is growing, including in a newly emerged resistant species. The candidate vaccine combines two fungal surface proteins produced in the laboratory, aiming for broad and lasting protection.
In mouse work the vaccine protected against bloodstream-spread infection by the main Candida species and by the resistant relative, and against mouth and throat type infection as well. It did not block antifungal drugs, and vaccine plus drug together trended toward better survival than either alone, though that gap was not statistically firm. Durable immunity is the promise highlighted.
Catalog record
| CREATOR | Shakti Singh, Eman G. Youssef, Ashley Barbarino, Haley Hautau, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Gary Ostroff, Dennis Christensen, Terrence Cochrane, Ashraf S. Ibrahim |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |